Syndax Pharmaceuticals/$SNDX
13:30
09:10
04:45
00:25
20:00
1D1W1MYTD1Y5YMAX
About Syndax Pharmaceuticals
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
Ticker
$SNDX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
270
ISIN
US87164F1057
Website
SNDX Metrics
BasicAdvanced
$848M
-
-$3.86
0.82
-
Price and volume
Market cap
$848M
Beta
0.82
52-week high
$25.07
52-week low
$8.58
Average daily volume
1.8M
Financial strength
Current ratio
5.804
Quick ratio
5.688
Long term debt to equity
153.956
Total debt to equity
160.714
Interest coverage (TTM)
-26.59%
Profitability
EBITDA (TTM)
-343.661
Gross margin (TTM)
-327.40%
Net profit margin (TTM)
-757.52%
Operating margin (TTM)
-786.03%
Revenue per employee (TTM)
$160,000
Management effectiveness
Return on assets (TTM)
-36.29%
Return on equity (TTM)
-93.70%
Valuation
Price to revenue (TTM)
19.344
Price to book
3.94
Price to tangible book (TTM)
3.94
Price to free cash flow (TTM)
-2.952
Free cash flow yield (TTM)
-33.88%
Free cash flow per share (TTM)
-333.70%
Growth
Earnings per share change (TTM)
18.94%
3-year revenue growth (CAGR)
-32.05%
3-year earnings per share growth (CAGR)
141.38%
10-year earnings per share growth (CAGR)
-39.22%
What the Analysts think about SNDX
Analyst ratings (Buy, Hold, Sell) for Syndax Pharmaceuticals stock.
Bulls say / Bears say
Syndax Pharmaceuticals' lead product, Revuforj® (revumenib), received FDA approval in November 2024 for treating relapsed or refractory acute leukemia with KMT2A translocation, marking it as the first and only menin inhibitor approved for this indication. (prnewswire.com)
In the first five weeks post-launch, Revuforj® generated $7.7 million in net product revenue, indicating strong initial market uptake. (prnewswire.com)
Barclays PLC increased its stake in Syndax Pharmaceuticals by 4.5% in the fourth quarter, reflecting growing institutional confidence in the company's prospects. (americanbankingnews.com)
Syndax reported a net loss of $94.2 million ($1.10 per share) in Q4 2024, with R&D expenses rising to $65.5 million and SG&A expenses increasing to $37.7 million, highlighting significant operational costs. (prnewswire.com)
Insider selling activity was noted, with CFO Keith A. Goldan selling 3,777 shares and insider Neil Gallagher selling 4,618 shares in February 2025, which may raise concerns about internal confidence. (etfdailynews.com)
StockNews.com downgraded Syndax Pharmaceuticals to a 'Sell' rating in April 2025, potentially indicating skepticism about the company's near-term performance. (marketbeat.com)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.
SNDX Financial Performance
Revenues and expenses
SNDX Earnings Performance
Company profitability
SNDX News
AllArticlesVideos
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewsWire·2 weeks ago
Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia
GlobeNewsWire·3 weeks ago
Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Syndax Pharmaceuticals stock?
Syndax Pharmaceuticals (SNDX) has a market cap of $848M as of July 15, 2025.
What is the P/E ratio for Syndax Pharmaceuticals stock?
The price to earnings (P/E) ratio for Syndax Pharmaceuticals (SNDX) stock is 0 as of July 15, 2025.
Does Syndax Pharmaceuticals stock pay dividends?
No, Syndax Pharmaceuticals (SNDX) stock does not pay dividends to its shareholders as of July 15, 2025.
When is the next Syndax Pharmaceuticals dividend payment date?
Syndax Pharmaceuticals (SNDX) stock does not pay dividends to its shareholders.
What is the beta indicator for Syndax Pharmaceuticals?
Syndax Pharmaceuticals (SNDX) has a beta rating of 0.82. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.